MedPath

Post-operative Monitoring of Gastric Cancer

Recruiting
Conditions
Gastric Cancer
Registration Number
NCT07026240
Lead Sponsor
Suzhou Huhu Health & Technology Inc.
Brief Summary

This study is to determine the performance of non-invasive new multi-target biomarkers in the post-operative monitoring of gastric cancer.

Detailed Description

This study aims to develop and validate a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood. Blood will also be collected at various time points post-operatively. We will determine whether these new biomarkers can be used as prognostic biomarkers to predict tumor recurrence and metastasis. We will also determine whether these new biomarkers detect tumor recurrence and metastasis earlier than methods currently used in the clinic such as imaging and tumor biomarkers CA19-9, CEA, and CA72-4.

This study is a prospective and multi-center study.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
258
Inclusion Criteria
  1. Subject age over 18.
  2. Subject has stomach discomfort, and seek medical attention at the Gastric Surgery Department of our center.
  3. Subject has or will have gastroscopy and/or pathological examination results at this center.
  4. Subject must be able to fully understand the informed consent form and be able to personally sign it.
Exclusion Criteria
  1. Subject has serious heart, liver, kidney dysfunction, or mental illness.
  2. Subject diagnosed previously with any kind of malignant tumor.
  3. Subject is known to be infected with HIV or other related diseases (considering interference from the use of immune drugs).
  4. Subject is receiving targeted drugs, immunosuppressants, immunomodulators, and biological therapies.
  5. Researchers believe that subject is not suitable for enrollment.
  6. Subject can not supply sufficient sample to complete this experiment.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The performance of the new biomarkers in the post-operative monitoring of gastric cancer2 years

Number of Participants With Tumor Recurrence Detected by the New System vs. Imaging and Serum Markers (CA19-9, CEA, CA72-4).

Secondary Outcome Measures
NameTimeMethod
Metastasis Detection Time: New vs. Conventional Methods2 years

Time to Detection of Metastasis (Days) by the New System Compared to Conventional Methods.

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center

🇨🇳

Shanghai, Shanghai, China

Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China
Dazhi Xu, MD., PhD
Contact
+8615862461212
jiangnan@sz-hoho.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.